Operating Margin % is calculated as Operating Income divided by its Revenue. UroGen Pharma's Operating Income for the
three
months ended in Mar. 2026 was €-17.5 Mil. UroGen Pharma's Revenue for the
three
months ended in Mar. 2026 was €44.1 Mil. Therefore, UroGen Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was -39.76%.
Good Sign:
UroGen Pharma Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for UroGen Pharma's Operating Margin % or its related term are showing as below:
FRA:UR8'
s Operating Margin % Range Over the Past 10 Years
Min: -608211.11 Med: -157.47 Max: 4.55
Current: -77.02
FRA:UR8's Operating Margin % is ranked better than 51.48% of 944
companies
in the Biotechnology industry
Industry Median: -86.83
vs FRA:UR8: -77.02
UroGen Pharma's 5-Year Average Operating Margin % Growth Rate was 31.90% per year.
UroGen Pharma's Operating Income for the
three
months ended in Mar. 2026 was €-17.5 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-93.1 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
UroGen Pharma Operating Margin % Related Terms
UroGen Pharma Operating Margin % Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs OCS, SEPN, AVBP: Operating Margin % Comparison
For the Biotechnology subindustry, UroGen Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
UroGen Pharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Operating Margin % of -39.76% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #458 out of 944 companies in the Biotechnology industry, placing it in the top 48.5%.
Is UroGen Pharma's Operating Margin % too high?
UroGen Pharma's current Operating Margin % is -39.76%. Based on the distribution chart, UroGen Pharma ranks #458 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Operating Margin % compare to OCS and SEPN?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #458 out of 944 companies for Operating Margin %. This puts UroGen Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Operating Margin % is -39.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.67, compared to a current price of €30.42 — trading 72.2% above its estimated fair value. The current Operating Margin % is -39.76%. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Operating Margin % is -39.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €30.42 is trading 72.2% above its estimated GF Value™ of €17.67.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Operating Margin %: -39.76%
GF Value™: €17.67 vs. price of €30.42 (72.2% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score
Get the complete analysis for FRA:UR8
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
